Skip to main content

Table 2 Clinical trials of CAR-T cells

From: Chimeric antigen receptor T cells: a novel therapy for solid tumors

Target

Identifier

Institution

Phase

Status

Disease

Comments

EGFR

NCT02331693

Shanghai Cancer Institute

I

Recruiting

Glioma

Autologous T cells transduced with a lentiviral vector

EGFRvIII

NCT02844062

Beijing Sanbo Brain Hospital

I

Recruiting

Glioma

Lymphodepletion chemotherapy, followed by CAR-T

EGFRvIII

NCT01454596

National Cancer Institute (NCI)

I/II

Recruiting

Glioma

Autologous T cells, a retroviral vector

EGFRvIII

NCT02209376

University of Pennsylvania/University of California

I

Recruiting

Glioma

Autologous T cells, a lentiviral vector

EGFRvIII

NCT02664363

Duke University Medical Center

I

Not yet recruiting

Glioma

Dose escalation cohorts for 4 dose levels

EGFR

NCT01869166

Chinese PLA General Hospital

I/II

Completed

NSCLC

Safe and feasible

HER2

NCT02713984

Southwest Hospital, China

I/II

Recruiting

HER2-positive cancer

 

HER2

NCT01935843

Chinese PLA General Hospital

I/II

Recruiting

HER2-positive cancer

 

HER2

NCT02547961

Fuda Cancer Hospital Guangzhou

I/II

Recruiting

Breast cancer

A retrovirus vector, preconditioning treatment

HER2

NCT02442297

Baylor College of Medicine

I

Recruiting

Glioma

Intracranial injection

HER2

NCT01109095

Baylor College of Medicine

I

Active, not recruiting

Glioma

CMV-specific cytotoxic T cells (CMV-T cells)

HER2

NCT00889954

Baylor College of Medicine

I

Active, not recruiting

HER2-positive cancer

TGFBeta resistant HER2/EBV-CTLs

HER2

NCT00924287

National Cancer Institute (NCI)

I/II

Completed

HER2-positive sarcoma

Results is not encouraging

HER2

NCT00902044

Baylor College of Medicine

I/II

Completed

HER2-positive sarcoma

Safe and feasible

MSLN

NCT02930993

China Meitan General Hospital

I

Recruiting

Mesothelin-positive tumors

Followed lymphodepletion

MSLN

NCT02706782

Shanghai Renji Hospital

I

Recruiting

Pancreatic cancer

Transcatheter arterial infusion

MSLN

NCT02159716

University of Pennsylvania

I

Active not recruiting

Mesothelin-positive tumors

Lentiviral transduced

MSLN

NCT02792114

Memorial Sloan Kettering Cancer Center

I

Recruiting

Mesothelin-expressing breast cancer

Premedicated with acetaminophen and diphenhydramine, and administered cyclophosphamide

MSLN

NCT02465983

University of Pennsylvania

I

Active not recruiting

Pancreatic cancer

Combination therapy with CART-meso cells and CART19 cells

MSLN

NCT02959151

Shanghai Tumor Hospital

I/II

Recruiting

Pancreatic cancer

Combined with interventional therapy

MSLN

NCT02590747

Chinese PLA General Hospital

I

Recruiting

Mesothelin-positive tumors

Retroviral vector-transduced

MSLN

NCT01355965

University of Pennsylvania

I

Completed

Pleural mesothelioma

Safe and feasible

MSLN

NCT02414269

Memorial Sloan Kettering Cancer Center

I

Recruiting

Malignant pleural disease

With/without chemotherapy

MSLN

NCT01583686

National Cancer Institute (NCI)

I/II

Recruiting

Mesothelin-positive tumors

Followed lymphodepletion

MSLN

NCT01897415

University of Pennsylvania

I

Active not recruiting

Pancreatic ductal adenocarcinoma (PDA)

Transfected with chimeric anti-mesothelin immunoreceptor SS1

IL13Rα2

NCT00730613

City of Hope Medical Center

I

Completed

Glioblastoma

Safe and feasible

IL13Rα2

NCT02208362

City of Hope Medical Center

I

Completed

Glioblastoma

Safe and feasible

CEA

NCT01373047

Roger Williams Medical Center

I

Completed

Liver metastases

Safe and feasible

FAP

NCT01722149

University of Zurich

I

Recruiting

Malignant pleural mesothelioma

Followed lymphodepletion

GD2

NCT00085930

Baylor College of Medicine

I

Completed

Neuroblastoma

Safe and feasible

GD2

NCT02107963

National Cancer Institute (NCI)

I

Completed

Sarcoma

Osteosarcoma

Neuroblastoma

Melanoma

Safe and feasible

CD133

NCT02541370

Chinese PLA General Hospital

I

Recruiting

CD133-positive malignancies

Relapsed and/or chemotherapy refractory advanced malignancies

  1. The details of Table 2 derived from http://clinicaltrials.gov/